ARWR ARROWHEAD PHARMACEUTICALS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: RNA interference (RNAi) therapeutics silencing disease-causing genes via proprietary TRiM delivery platform
• • New commercial product: REDEMPLO® (plozasiran) FDA approved in 2025 for Familial Chylomicronemia Syndrome (FCS)
• • Strategic shift: Building commercial infrastructure for rare FCS and expansion to severe hypertriglyceridemia (sHTG) market with Phase 3 trials underway
• • Notable metric: 18 wholly-owned RNAi drug candidates in clinical trials from Phase 1 to Phase 3, plus multiple new candidates annually in discovery pipeline
• • Unique fact: Entered global licensing and collaboration agreements in 2024-2025 with Sarepta for rare disease RNAi therapies and Novartis for Parkinson’s-related program

Risk Factors

• • Regulatory risk from FDA clinical trial authorizations for ARO-DM1 affecting milestone payments ($100M milestone triggered Nov 2025)
• • Geopolitical risk limited; primary macro exposure through $500M upfront from Sarepta and $200M from Novartis licensing agreements in FY 2025
• • Operational risk in R&D pipeline dependency on clinical enrollment targets for multiple RNAi therapeutics, critical for milestone payments up to $250M
• • Competitive risk from Sarepta collaboration, potential market disruption due to Sarepta's vested interest and shared RNAi therapeutic platforms
• • Financial risk from $500M senior secured Credit Facility with $201.6M repayments in FY 2025, indicating leverage and refinancing requirements

Management Discussion & Analysis

• • Cash, cash equivalents, short-term investments sufficient for near-term needs as of Sept 30, 2025
• • Capital expenditures $12.5M in 2025, $136.9M in 2024 for manufacturing facility build-out; $0.1M more expected
• • Operating lease obligations $111.4M total, $7.3M due within 12 months
• • Secured term loan facility $500M; $400M funded, $100M optional; $106.7M prepayments including $66.7M in Nov 2025
• • Commitments for clinical, manufacturing, business agreements $665.5M as of Sept 30, 2025; many cancellable

What are the latest ARWR SEC filings in 2026?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has filed a 10-K annual report on November 25, 2025, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ARWR file its most recent 10-K annual report?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its most recent 10-K annual report on November 25, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ARWR 10-Q quarterly reports?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every ARWR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ARWR filed recently?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ARWR insider trading activity (Form 4)?

SignalX aggregates every ARWR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ARWR file with the SEC?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ARWR filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).

What is ARWR's SEC CIK number?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s SEC CIK (Central Index Key) number is 879407. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 879407 to look up all ARWR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ARWR return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from ARROWHEAD PHARMACEUTICALS, INC. (ARWR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.